Overview
- BullFrog AI’s agreement, announced Monday, sent the company’s shares up more than 100% during regular trading.
- The collaboration uses BullFrog’s bfLEAP system to identify and rank new targets for major depressive disorder, with the partner gaining exclusive access to one candidate.
- A Tuesday update from CoinCentral reports a one-year feasibility contract signed March 27 that could grant up to three years of exclusivity on the final selected target.
- The same report says the deal includes milestone payments tied to deliverables such as prioritized targets, causal gene networks, and target dossiers, with the client able to terminate on 30 days’ notice.
- The pharma company remains unnamed, and BullFrog says a forthcoming SEC Form 8-K will lay out terms, as the company points to an MDD market projected to grow from over $8 billion in 2025 to more than $11 billion by 2032.